IRWD

AI Memo

Ironwood

As of 2026-10-16/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-16 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Further debt reduction through year-end • 2026-12-31

Base target: $4 / p=50% prob

Biggest risk

The thesis remains dependent on sustaining LINZESS net price and prescription demand while funding and executing a confirmatory Phase 3 trial. Trial timing and outcome remain uncertain. [#SEC-8K-2026-08-06]

Invalidation

Break below $3 or thesis failure.

What would change my mind?

The raised LINZESS guidance, Q2 profitability, and repayment of convertible notes support a cash-generation thesis; successful STARS-2 execution offers longer-term diversification. The guidance increase and Q2 results are already public. [#SEC-8K-2026-08-06]

Research note

Recommendation

—

Confidence

medium

As of

2026-10-16

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Execution against raised 2026 LINZESS guidance
Apraglutide STARS-2 trial execution
The raised LINZESS guidance, Q2 profitability, and repayment of convertible notes support a cash-generation thesis; successful STARS-2 execution offers longer-term diversification.

BearKey bullets

Further debt reduction depends on continued cash generation; the amount and timing beyond the reported Q2 repayment are unspecified.
[#SEC-8K-2026-08-06]
LINZESS net-price or prescription-demand weakness could undermine raised 2026 guidance.

WatchKey bullets

Further debt reduction through year-end

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $4 (p=50%)

Target spread vs base: +28% / -34%

Scenario probabilities

Bull Target: $5 (p=25%)Base Target: $4 (p=50%)Bear Target: $3 (p=25%)

Commentary

The August company release was favorable, but the supplied news is largely from August and does not establish current 30-day tone or a verified post-release price reaction. Analyst revisions, target changes, and current social, options, short-interest, and employee measurements are unavailable; zero-valued fields denote unavailable data, not neutral observations. The deterministic directional prior is neutral despite strong primary-source context.

As of 2026-10-16 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Execution against raised 2026 LINZESS guidance
Apraglutide STARS-2 trial execution

Scenarios

Bull Target (Scenario probability)

$5 / p=25% prob

Base Target (Scenario probability)

$4 / p=50% prob

Bear Target (Scenario probability)

$3 / p=25% prob

Analysis 2026-10-16 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Further debt reduction through year-end
Ironwood reported repaying $200 million of convertible notes with cash on hand in Q2 and said it remained committed to further debt reduction through year-end. Further progress could strengthen the balance-sheet case, but the supplied evidence does not establish an amount or transaction date. [#SEC-8K-2026-08-06]
Prob 60.00% • Move 7.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Execution against raised 2026 LINZESS guidance
2026-12-31
After Q2 U.S. LINZESS net sales of $282 million, Ironwood raised 2026 U.S. LINZESS sales guidance to $1.15–$1.20 billion, total revenue guidance to $460–$485 million, and adjusted EBITDA guidance to more than $310 million. Management attributed the improvement to net price and mid-single-digit prescription-demand growth. Sustaining those drivers—not the already-announced guidance raise—is the forward test. [#8-K-2026-08-06] [#SEC-8K-2026-08-06]
Prob 65% • Move 10% • Priced-in 75%

Long-term Catalysts

Months to a year

Apraglutide STARS-2 trial execution
2027-06-30
Ironwood said its confirmatory Phase 3 STARS-2 trial in short bowel syndrome with intestinal failure was actively recruiting. Enrollment and development progress could diversify the company beyond LINZESS, but no readout or approval date is established here; the stated date is a monitoring horizon, not a company milestone. [#SEC-8K-2026-08-06]
Prob 50% • Move 20% • Priced-in 30%

Risks

Further debt reduction depends on continued cash generation; the amount and timing beyond the reported Q2 repayment are unspecified. [#SEC-8K-2026-08-06]
LINZESS net-price or prescription-demand weakness could undermine raised 2026 guidance. [#SEC-8K-2026-08-06]
Low analyst coverage visibility and loose peers limit confidence in target-based valuation.
STARS-2 recruitment, confirmatory results, and eventual regulatory review carry development risk; no readout date is established in the supplied evidence. [#SEC-8K-2026-08-06]

Peers

Symbol	Summary
AMGN	Broad commercial-biopharma reference only; its substantially greater scale and diversification make it a weak direct valuation comparable.
NVCT	Similar market capitalization in the supplied peer set, but no evidence establishes a direct comparison with Ironwood's LINZESS cash flows.
CLYM	Similar market capitalization in the supplied peer set, but no evidence establishes comparable marketed-product economics; use only as a loose size reference.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-16

Loading AI feed…

Symbol

Summary

AMGN

Broad commercial-biopharma reference only; its substantially greater scale and diversification make it a weak direct valuation comparable.

NVCT

Similar market capitalization in the supplied peer set, but no evidence establishes a direct comparison with Ironwood's LINZESS cash flows.

CLYM

Similar market capitalization in the supplied peer set, but no evidence establishes comparable marketed-product economics; use only as a loose size reference.